MeSH term
Frequency | Condition_Probility | Humans | 32 | 0.0 |
Stereoisomerism | 2 | 0.0 |
Substrate Specificity | 3 | 0.0 |
Escherichia coli | 2 | 0.0 |
Kinetics | 7 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 13 | 0.0 |
Amino Acid Sequence | 2 | 0.0 |
Animals | 5 | 0.0 |
Base Sequence | 2 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Molecular Sequence Data | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Comparative Study | 2 | 0.0 |
Cytidine Deaminase/*antagonists & inhibitors | 2 | 100.0 |
Mice | 3 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Catalysis | 2 | 0.0 |
Escherichia coli/genetics | 2 | 0.0 |
Female | 11 | 0.0 |
Middle Aged | 7 | 0.0 |
Adult | 6 | 0.0 |
Aged | 3 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
Male | 10 | 0.0 |
Prognosis | 2 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Binding Sites | 2 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 2 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Polymerase Chain Reaction | 3 | 0.0 |
Cladribine/*pharmacology | 2 | 20.0 |
Child, Preschool | 2 | 0.0 |
